From: <b class="gmail_sendername">Amit Sengupta</b> <span dir="ltr"><<a href="mailto:asengupta@phmovement.org" target="_blank">asengupta@phmovement.org</a>></span><br><div class="gmail_quote"><div><div class="gmail_quote">
<div style="font-size:14px;font-family:Calibri,sans-serif;word-wrap:break-word">
<div><div><div><span style="font-size:medium"><div><span style="font-family:Calibri"><span style="font-size:14px;font-family:Calibri,sans-serif"><div><div style="font-size:14px;font-family:Calibri,sans-serif;word-wrap:break-word">
<span style="font-family:Calibri,sans-serif"><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word">
<span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word">
<span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span style="font-size:medium"><span style="font-family:Calibri"><span style="font-size:14px;font-family:Calibri,sans-serif">From: Sangeeta Shashikant TWN<span style="font-family:Calibri,sans-serif"><div>
<div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div>
<div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div>
<div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><div>
</div>
</div>
</div>
</span>
<br></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></div></div></span></span></span></span><span><div>
<div style="font-family:Calibri,sans-serif;word-wrap:break-word">
<div>
<div>
<div>The letter below will be sent to all WTO missions in Geneva. It can also be useful for lobbying national governments. </div>
</div>
</div>
</div>
</div>
</span>
<div><br>
</div>
<span>
<div>
<div style="font-family:Calibri,sans-serif;word-wrap:break-word">
<div>
<div><b>If you organisation is able to support this joint NGO letter, please send an email to to <a>sangeeta@twnetwork.org </a></b><b><u></u>with the name of your organisation and the country where it is based. </b></div>
</div>
</div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span>
<div><br>
</div><span style="font-family:Calibri,sans-serif"></span>Third World Network<span style="font-family:Calibri,sans-serif"><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word">
<span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word">
<span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word"><span><div><div style="font-family:Calibri,sans-serif;word-wrap:break-word">
</div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div>
</span></div>
</div></span><span><div><div style="word-wrap:break-word"><br><div style="font-family:Calibri,sans-serif;font-size:14px">-------------------------------------------------------------------------------------------------------</div>
<div>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:center" align="center">
<b>
</b></p>
<p style="font-size:14px;text-align:left;font-family:Calibri,sans-serif" align="center">
<b>NGO LETTER TO WTO MEMBERS CONCERNING A FURTHER EXTENSION OF THE LDC TRANSITION PERIOD UNDER ARTICLE 66.1 OF THE TRIPS AGREEMENT</b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif">
<b>Dear WTO Members,<u></u><u></u></b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
As civil society organisations concerned with access to medicines, to educational resources, to environmentally sound technologies (ESTs), and to other public goods and cultural creations and further concerned with farmers’ rights, food security, human flourishing,
sustainable and equitable technological and industrial development in LDC countries, <b>we call on WTO Members tounconditionally accord the LDC Group an extension of the transition period as requested by the LDC Group in their duly motivated request to the
TRIPs Council (IP/C/W/583).<u></u><u></u></b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
Article 66.1 of the TRIPS Agreement accorded LDC Members a renewable ten-year exemption from most obligations under the TRIPS Agreement in view of the special needs and requirements of the LDC Members, their economic, financial and administrative constraints
and their need for flexibility to create a viable technological base<a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftnref1" title=""><span><span><span><span style="font-family:Calibri">[1]</span></span></span></span></a>.<u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
This exemption was originally due to expire on 31 December 2005. However, a TRIPS Council decision of 27 June 2002 (IP/C/25), exempted LDCs from having to implement or enforce patents and test data obligations with regard to pharmaceutical products until 1
January 2016. Without prejudice to this extension, the TRIPS Council, through its decision IP/C/40, extended the general TRIPS compliance transition period for LDC Members for all obligations under the TRIPS Agreement, other than Articles 3, 4 and 5, until
1 July 2013 or until such date on which a Member ceases to be an LDC, whichever date is earlier.<u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
<b>On 5 November 2012 the Delegation of Haiti on behalf of the LDC Group submited a duly motivated request to the WTO TRIPS Council for an extension of the LDC transition period, until a Member ceases to be a LDC (IP/C/W/583).<span> </span>Annexed to the request
is a draft decision text for the consideration of the TRIPS Council. The draft decision states: “</b><b><span lang="EN-US">Least developed country Members shall not be required to apply the provisions of the Agreement, other than Articles 3, 4 and 5, until
they cease to be a least developed country Member”.<u></u><u></u></span></b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
<b>We are of the view that Article 66.1 obliges the TRIPS Council to approve without conditions the duly motivated request submitted by the LDCs. Thus we strongly urge all WTO Members to urgently support the LDC Group request and to approve the LDC request
and proposed draft decision.<span></span><u></u><u></u></b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
LDCs are fully justified in seeking an unlimited extension for so long as any LDC Member is so classified because shorter extensions, even sequential extensions, will not give LDCs adequate time to overcome capacity constraints and to develop a viable and competitive
technological base. By definition, LDCs face ongoing resource and human constraints, widening technological gaps, and weak innovative capacities.<span> </span>Overcoming these problems takes contextually specific strategies, policy flexibility, greater financial
resources, but it also takes time – decades not years.<u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
Similarly, LDCs are fully justified in seeking a group extension rather than individual country extensions and in seeking extensions with respect to all TRIPS obligations rather than select obligations only.<span> </span>LDCs, by definition, are similarly
situated with respect to development challenges and they should have full flexibility as a group.<span> </span><u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
LDCs are also fully justified in not promising to maintain current levels of IP protections. <span> </span>LDCs must not be asked to undertake additional obligations such as those contained in paragraph 5 of IP/C/40. This paragraph is based on Article 65 of
TRIPS but it only applies to developing countries and not to LDCs. Conditions such as paragraph 5 of IP/C/40 narrows the policy space available to LDCs by cementing colonial era IP rules and ill-advised IP reforms. <span> </span>LDCs should have full flexibility
and policy space as permitted under Article 66.1 of TRIPS including the option to undo existing IP protections. Article 66.1 of TRIPS does not permit the TRIPS Council to attach conditions when granting an extension as per the duly motivated request of LDCs.<u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
We are of the view that failure by the TRIPS Council to grant LDCs an extension would be disastrous for LDC Members and their citizens. LDCs would immediately need to amend their intellectual property laws to become TRIPS-compliant and would be under extreme
time pressures to do so. Much worse, they would be adopting high standards of intellectual property protection and enforcement before they have had any real domestic technological capacity and before a significant body of local inventors, authors, and creators
could leverage a domestic intellectual property system to their advantage.<u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
It is a fact that in LDC countries foreign individuals and companies are the main beneficiaries of expanded IP protection and these foreign right holders tend to set high monopoly prices, which are unaffordable to most of the population. Moreover, historically
most technological development in developing and even in developed countries has come through a period of copying and adapting advanced technologies initially invented elsewhere.<a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftnref2" title=""><span><span><span><span style="font-family:Calibri">[2]</span></span></span></span></a><u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
Many LDC Members, pursuant to misguided advice, have been focusing on becoming TRIPS compliant. We believe that this is the wrong focus as generally LDCs are not in a position to benefit from full TRIPS compliance. In any case, the TRIPS transition period provides
LDCs ample flexibility to implement the level of intellectual property protection suitable for individual interests and needs.<u></u><u></u></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
<span style="font-family:Calibri">Finally approving the LDC group request would also effectively extend the waiver issued to LDCs with regard to pharmaceutical products (due to expire in 2016). LDCs suffer from multiple disease burdens. For instance </span><span style="font-family:Calibri" lang="EN-US">most
LDCs are from sub-Saharan Africa, which has a high concentration of AIDS epidemic. </span><span style="font-family:Calibri">Thus the request is important to the continued ability of LDC to access affordable generic medicines of assured quality for HIV/AIDS,
TB, malaria and other infectious, neglected, and non-communicable diseases and to allow LDCs to develop local pharmaceutical capacity. Indeed, LDC Members, could fill an important pharmaceutical niche by manufacturing newer medicines now patented in key producer
countries like India, all of which were required to become TRIPS-compliant in 2000 or 2005.</span></p>
<span style="font-family:Calibri"></span>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
The crucial issue of an LDC extension with respect to pharmaceuticals has been raised by the the Global Commission on HIV and the Law made up of former heads of state and leading legal, human rights and HIV experts, and supported by the UN Development Programme
(UNDP) on behalf of the Joint United Nations Programme on HIV/AIDS (UNAIDS).<span> </span>In its final report, <span>the Commission states that "When the product is pharmaceuticals, the outcome [of TRIPS regulation] for poor countries with overwhelming HIV
epidemics and other health challenges has been catastrophic. It is an indictment of the current international IP regime that it has not resulted in increased innovation for medicines to treat HIV co-infections such as tuberculosis, hepatitis C or related diseases
that predominantly affect the poor.”<a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftnref3" title=""><span><span><span><span style="font-family:Calibri">[3]</span></span></span></span></a> The
Commission therefore recommended <span>that </span>"<span>The WTO members must indefinitely extend the exemption for LDCs from the application of TRIPS provisions in the case of pharmaceutical products. The UN
and its member states must mobilise adequate resources to support LDCs to retain this policy latitude.</span>"<a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftnref4" title=""><span><span><span><span><span style="font-family:Calibri">[4]</span></span></span></span></span></a><span><u></u><u></u></span></span></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
<b>In conclusion we request that:<u></u><u></u></b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;margin-left:14.2pt;text-align:justify">
<span>·<span style="font:normal normal normal 7pt/normal 'Times New Roman';font-family:Calibri"> </span></span><b>All WTO Members honor their obligation under Article 66.1 and unconditionally accord to the Least Developed Countries the requested extension.
Accordingly all WTO Members should support and agree at the upcoming meetings of the TRIPS Council to the draft decision text presented by the LDC Group that: “</b><b><span lang="EN-US">Least developed country Members shall not be required to apply the provisions
of the Agreement, other than Articles 3, 4 and 5, until they cease to be a least developed country Member”</span></b><b><u></u><u></u></b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;margin-left:14.2pt;text-align:justify">
<span>·<span style="font:normal normal normal 7pt/normal 'Times New Roman';font-family:Calibri"> </span></span><b><span style="font-family:Times" lang="FR"><span style="font-family:Calibri">WTO Members do NOT attach to the extension decision
any conditions and limitations that limit the policy space and flexibility available to LDCs under Article 66.1 of TRIPS, such as those contained in paragraph 5 of IP/C/40.</span><span style="font-family:Calibri"> </span></span></b><b><u></u><u></u></b></p>
<p style="font-size:14px;font-family:Calibri,sans-serif;text-align:justify">
<b>In conclusion, </b><b><span style="font-family:Times" lang="FR"><span style="font-family:Calibri">we stress that any attempt to weaken or to refuse Least Developed Countries (LDCs) rights that they are entitled to under the TRIPS Agreement will damage
the credibility of the WTO as it will show that the multilateral trading system is unable to benefit the poorest and most vulnerable segment of the international community.</span><span style="font-family:Calibri"><u></u><u></u></span></span></b></p>
<p style="font-family:Calibri,sans-serif">
<b><span style="font-family:Calibri" lang="FR"><u></u></span></b><a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftn1" title=""><span><span lang="FR"><span><span style="font-family:Calibri" lang="FR">[1]</span></span></span></span></a><span lang="FR"></span><span style="font-family:Calibri" lang="FR">Article
66.1 of the TRIPS Agreement states: “In view of the special needs andrequirements of least-developed country Members, </span><span style="font-family:Calibri">their economic, financial and administrative constraints, and their need
for flexibility to create a viable technological base, such</span></p><div style="font-family:Calibri,sans-serif"><div>
<p style="font-family:Calibri,sans-serif"><span style="font-family:Calibri" lang="FR">Members shall not be required to apply the provisions of this Agreement, other than Article 3, 4, and 5, for a period of 10 years from </span><span style="font-family:Calibri">the
date of application as defined under paragraph 1 of Article 65. The Council for TRIPS shall, upon duly motivated request by a</span></p>
<p style="font-family:Calibri,sans-serif"><span style="font-family:Calibri" lang="FR">least-developed country Member, accord extensions of this period.”</span><span lang="EN-US"><u></u><u></u></span></p>
</div>
<div style="font-family:Calibri,sans-serif">
<p style="margin-left:0cm;text-indent:0cm"><a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftn2" title=""><span><span lang="FR"><span><span><span style="font-family:Calibri" lang="FR">[2]</span></span></span></span></span></a><span style="font-family:Calibri" lang="FR"> This
trend is aptly captured by Ha-Joon Chang: “....when they were backward themselves in terms of knowledge, all of today’s rich countries blithely violated other people’s patents, trademarks and copyrights. The Swiss “borrowed” German chemical inventions, while
the Germans “borrowed” English trademarks” and the Americans “borrowed” British copyrighted materials – all without paying what would today be considered “just” compensation” ;</span><span style="font-family:Calibri" lang="FR"> Ha-Joon Chang (2007), “Bad
Samaritans The Guilty Secrets of Rich Nations & the Threat to Global Prosperity”</span><span style="font-family:Calibri" lang="EN-US"><u></u><u></u></span></p>
</div>
<div style="font-family:Calibri,sans-serif">
<p><a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftn3" title=""><span><span lang="FR"><span><span><span style="font-family:Calibri" lang="FR">[3]</span></span></span></span></span></a><span lang="FR"><span style="font-family:Calibri"> </span><span style="font-family:Calibri">« HIV
and the Law : Risks, Rights & Health », final report of the Global Commission on HIV and the Law, p. 80.</span><span style="font-family:Calibri"></span></span></p>
</div>
<div style="font-family:Calibri,sans-serif">
<p><a name="13cb7681dfe8edda_13cb3cbeae345598_13cafea27fcc17a8__ftn4" title=""><span><span lang="FR"><span><span style="font-family:Calibri" lang="FR">[4]</span></span></span></span></a><span lang="FR"><span style="font-family:Calibri"> </span><span style="font-family:Calibri">Idem.
p. 87.</span></span></p>
</div>
</div>
</div>
</div>
</div>
</span></span></div>
<div><font face="Calibri,Verdana,Helvetica,Arial"></font></div>
</span></div>
<div><font face="Calibri,Verdana,Helvetica,Arial"><span style="font-size:11pt">
<div><br>
</div>
</span></font></div>
</div>
</div>
</div>
</div><br></div>
</div><br>